** Shares of CSPC Pharmaceutical Group 1093.HK jump 9.6% to HK$6.51, their highest levels since October 22
** Stock on course for a third straight session of gains, if current trend holds
** Stock marks the biggest intraday pct gain since April 1 and is third-biggest pct gainer in the Hong Kong's healthcare index .HSCIH, which rises 3%
** CSPC says its epidermal growth factor receptor antibody drug conjugate - CPO301 - has been granted the third Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced lung cancer
** CPO301 is undergoing clinical studies in China and the U.S. and the granting of Fast Track designation by the FDA will facilitate and expedite the development and registration of CPO301 in the U.S. and globally - CSPC
** Hang Seng Biotech Index .HSHKBIO rises 3.5%, Hang Seng Index .HSI climbs 1%
** YTD, stock up 32.6%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。